Results 331 to 340 of about 355,709 (346)
Some of the next articles are maybe not open access.
memo - Magazine of European Medical Oncology, 2012
The current gold standard of care for first-line therapy in patients with nonsmall cell lung cancer (NSCLC) is a platinum-based doublet chemotherapy, which is recommended for a maximum of six cycles. Since the prolongation of the first-line regimen does not translate into improved survival, and most patients experience progression within 3–4 months ...
openaire +2 more sources
The current gold standard of care for first-line therapy in patients with nonsmall cell lung cancer (NSCLC) is a platinum-based doublet chemotherapy, which is recommended for a maximum of six cycles. Since the prolongation of the first-line regimen does not translate into improved survival, and most patients experience progression within 3–4 months ...
openaire +2 more sources
Nature Medicine, 2020 Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC
Nature Reviews Clinical Oncology, 2019D. Camidge, R. Doebele, Keith M. Kerr
semanticscholar +1 more source
Atezolizumab Treatment of Nonsquamous NSCLC
New England Journal of Medicine, 2018Martin Reck +2 more
openaire +4 more sources
Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice
Nature Reviews Clinical Oncology, 2020C. Aggarwal +5 more
semanticscholar +1 more source
Understanding and targeting resistance mechanisms in NSCLC
Nature Reviews. Cancer, 2017J. Rotow, T. Bivona
semanticscholar +1 more source